According to a recent Lex Machina report, the number of Abbreviated New Drug Application (ANDA) patent litigation filings increased 68% from 2014-2015. In the five years prior, an average of 269 cases were filed each year, but from 2014-2015, the average rose to 451 cases. In the report, Finnegan is cited as one of the top firms filing ANDA lawsuits on behalf of plaintiffs with 274 cases. While ANDA cases only make up approximately 10 percent of all patent filings, this increase is a sign that things are becoming intense in the pharmaceutical industry.
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.